Fig. 1: SCLC cellular models allow for in vitro modeling of acquired resistance and response and relapse dynamics.
From: Targeting PEA3 transcription factors to mitigate small cell lung cancer progression
A Experimental timeline of chemotherapy exposure. B Demonstration of in vitro acquired resistance in H524 with iterative rounds of cisplatin treatment at 1 μM concentration. Viable cell number at each time point was measured in triplicate. C Cisplatin and etoposide dual titrations for determination of treatment concentrations. Estimated IC50 doses by line are as follows: cisplatin 500 nM etoposide 500 nM for H82 and H526, cisplatin 1 μM etoposide 1 μM for H1963. D Response and regrowth curves following 72 h treatment with combination cisplatin and etoposide at experimentally determined 72-h IC50 doses. Viable cell number at each time point was measured in triplicate. E EdU labeling at various time points following cisplatin 500 nM and etoposide 500 nM exposure for 72 h in H82.
